Avoid common mistakes on your manuscript.
GlaxoSmithKline has announced that it intends to donate 50 million doses of H5N1 adjuvanted pre-pandemic influenza vaccine to the WHO. These doses are sufficient to vaccinate 25 million people (2 injections per person), and are to be delivered over a 3-year period. GlaxoSmithKline made this move in response to the WHO's initiative to establish an international stockpile of H5N1 pre-pandemic vaccines.* The company has also confirmed that it intends to make additional doses of its vaccine available to the WHO at preferential prices for GAVI-eligible countries, and is prepared to make its adjuvant available for public purchase by governments.
therapeutic use - Influenza-A-virus-vaccine-H5N1 - Vaccines - Influenza-virus-infections - prevention - Healthcare-news - Health-services-accessibility - GlaxoSmithKline - Research-and-development
* See PharmacoEconomics and Outcomes News 528 p10
REFERENCE
GlaxoSmithKline.GlaxoSmithKline to Make Unprecedented Vaccine Donation to WHO Pandemic Flu Stockpile. Media Release: 13 Jun 2007. Available from: URL: http://www.gsk.com
Rights and permissions
About this article
Cite this article
GlaxoSmithKline has announced that it intends to donate 50 million doses of H5N1 adjuvanted pre-pandemic influenza vaccine to the WHO.. Pharmacoecon. Outcomes News 531, 11 (2007). https://doi.org/10.2165/00151234-200705310-00022
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705310-00022